CDKN2A mutation analysis, protein expression, and deletion mapping of chromosome 9p conventional clear-cell renal carcinomas: Evidence for a second tumor suppressor gene proximal to CDKN2A

American Journal of Pathology

Volumn 158, Issue 2, 2001, Pages 593-601

  Schraml, P ^a   Struckmann, K ^a   Bednar, R ^a   Fu, W ^a   Gasser, T ^a   Wilber, K ^a   Kononen, J ^a   Sauter, G ^a   Mihatsch, M J ^a   Moch, H ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN CDKN2A; UNCLASSIFIED DRUG; DNA; MICROSATELLITE DNA; PROTEIN P16INK4A;

ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 9P; CHROMOSOME MAP; CLEAR CELL CARCINOMA; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE INACTIVATION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CHEMISTRY; CHROMOSOME 9; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETICS; IMMUNOHISTOCHEMISTRY; KIDNEY TUMOR; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; POINT MUTATION; SURVIVAL;

ADENOCARCINOMA, CLEAR CELL; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BASE SEQUENCE; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MOLECULAR SEQUENCE DATA; MUTATION; POINT MUTATION; POLYMORPHISM, GENETIC; SEQUENCE DELETION; SURVIVAL ANALYSIS;

EID: 0034746254     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64001-1     Document Type: Article

References (61)

1. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas
2. Comprehensive allelotyping of human renal cell carcinomas using microsatellite DNA probes
3. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma
4. Contribution of chromosome 9p21-22 deletion to the progression of human renal cell carcinoma
5. Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization
6. The CDKN2A (p16) gene and human cancer
7. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
8. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction
9. Rates of p16 (MTS1) mutations in primary tumors with 9p loss
10. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
11. Rates of p16 (MTS1) mutations in primary tumors with 9p loss
12. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
13. A cell cycle regulator potentially involved in genesis of many tumor types
14. The Heidelberg classification of renal cell tumours
15. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas): The basic cytological and histopathological elements and their use for diagnostics
16. A novel p16INK4A transcript
17. Allelic loss at the D9S171 locus on chromosome 9p13 is associated with progression of papillary renal cell carcinoma
18. Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer
19. Tissue microarrays for high-throughput molecular profiling of tumor specimens
20. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma
21. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
22. Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis
23. Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology
24. Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas
25. Homozygous deletions within human chromosome band 9p21 in melanoma
26. Mutations in the CDKN2A (p16INK4a) gene in microdissected sporadic primary melanomas
27. Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer
28. Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: Evidence for common founders and independent mutations
29. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds
30. Functional reassessment of P16 variants using a transfection-based assay
31. CDKN2A mutations in multiple primary melanomas
32. Germline p16 mutations in familial melanoma
33. Homozygous deletion of the p16INK4a and the p15INK4b tumour suppressor genes in a subset of human sporadic cutaneous malignant melanoma
34. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors
35. Mutations associated with familial melanoma impair p16INK4 function
36. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p
37. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers
38. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL-independent pathway in clear cell renal tumourigenesis
39. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing
40. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma
41. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer
42. G1 control gene status is frequently altered in resectable non-small cell lung cancer
43. Alteration of p16 and p15 genes in common epithelial ovarian tumors
44. Retinoblastoma and p16 proteins in mammary carcinoma: Their relationship to cyclin D1 and histopathological parameters
45. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis
46. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence
47. A comparison of p53 and p16 expression in human tumor cells treated with hyperthermia or ionizing radiation
48. Accumulation of p16CDKN2A in response to ultraviolet irradiation correlates with late S-G(2)-phase cell cycle delay
49. Frequent loss of chromosome 9 in human primary non-small cell lung cancer
50. 9p21 deletion correlates with recurrence in head and neck cancer
51. Loss of heterozygosity of microsatellite loci on chromosome 9p in astrocytic tumors and its prognostic implications
52. Fequent allele loss on 9p21-22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer
53. Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus
54. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma
55. Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas
56. Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: Evidence for two deleted regions
57. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma
58. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: The deleted region involves markers outside of the MTS1 and MTS2 genes
59. Homozygous deletions at 9p21 in childhood acute lymphoblastic leukemia detected by microsatellite analysis